Pioglitazone and TKI [USA]

Study title

Pioglitazone and Tyrosine Kinase Inhibitor in Patients with Relapsed CML [USA]

Scientific title

Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia (NCT 02730195).

Indication and most important inclusion criteria

This study includes patients 16 years and older with chronic myeloid leukemia (CML) in any phase. Patients are eligible for inclusion if they have lost major molecular response (MMR) after a first tyrosine kinase inhibitor (TKI) stop trial.

Short description of intervention

This is a study to find out if pioglitazone hydrochloride enhances the activity of tyrosine kinase inhibitor therapy in patients with CML that has come back after a first TKI discontinuation. The success of the combination is measured by the rate of successful second discontinuation of TKI. Pioglitazone hydrochloride is a drug approved in the USA to treat diabetes and has been shown in laboratory studies to increase CML stem cell death when given together with TKI therapy.

Patients receive pioglitazone hydrochloride by mouth once daily on days 1-28. Patients also start or continue the same TKI therapy as before stopping. Courses repeat every 28 days for 6 months unless the disease progresses or unacceptable side effects occur.

Type of study

Therapy optimization trial

Current status

recruiting

Study sponsor

Emory University, Georgia, USA

Scientific lead / contact

Shannon Gleason

Principal investigator

Vamsi Kota, MD

Additional information

Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health

Study centers / principal investigators

Emory University/Winship Cancer Institute
Vamsi Kota, MD
Georgia, 30322
United States